ABSTRACT

The present application describes novel hydantoin derivatives of formula (I):



(I)

or pharmaceutically acceptable salt or prodrug forms thereof, wherein L, Z^0, R^1, R^4, R^5, and R^{11} are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.